Tectonic Therapeutic (TECX) Projected to Post Earnings on Thursday

Tectonic Therapeutic (NASDAQ:TECX) is anticipated to post its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of ($1.3488) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 13, 2026 at 4:00 PM ET.

Tectonic Therapeutic (NASDAQ:TECX) last posted its earnings results on Thursday, May 7th. The company reported ($1.34) EPS for the quarter, missing the consensus estimate of ($1.16) by ($0.18). On average, analysts expect Tectonic Therapeutic to post $-5 EPS for the current fiscal year and $-6 EPS for the next fiscal year.

Tectonic Therapeutic Price Performance

TECX opened at $29.17 on Wednesday. Tectonic Therapeutic has a fifty-two week low of $14.39 and a fifty-two week high of $39.53. The company’s 50 day moving average price is $31.25 and its two-hundred day moving average price is $28.32. The firm has a market capitalization of $550.44 million, a price-to-earnings ratio of -6.54 and a beta of 3.28.

Analysts Set New Price Targets

TECX has been the topic of a number of recent research reports. Zacks Research lowered shares of Tectonic Therapeutic from a “hold” rating to a “strong sell” rating in a report on Monday, July 20th. Stifel Nicolaus started coverage on Tectonic Therapeutic in a report on Monday, April 13th. They issued a “buy” rating and a $75.00 price objective for the company. Wall Street Zen downgraded Tectonic Therapeutic from a “sell” rating to a “strong sell” rating in a report on Saturday, April 18th. Raymond James Financial raised Tectonic Therapeutic from an “outperform” rating to a “strong-buy” rating and raised their target price for the stock from $76.00 to $81.00 in a research report on Tuesday, May 26th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tectonic Therapeutic in a report on Friday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $79.40.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Braidwell LP lifted its position in shares of Tectonic Therapeutic by 25.9% in the 4th quarter. Braidwell LP now owns 927,524 shares of the company’s stock worth $19,348,000 after purchasing an additional 190,657 shares during the period. Orbimed Advisors LLC acquired a new stake in shares of Tectonic Therapeutic during the fourth quarter worth $11,986,000. Vestal Point Capital LP acquired a new stake in shares of Tectonic Therapeutic during the fourth quarter worth $6,842,000. Millennium Management LLC increased its position in shares of Tectonic Therapeutic by 26.3% during the fourth quarter. Millennium Management LLC now owns 300,820 shares of the company’s stock worth $6,275,000 after buying an additional 62,650 shares during the period. Finally, Citadel Advisors LLC raised its stake in Tectonic Therapeutic by 80.8% during the third quarter. Citadel Advisors LLC now owns 298,388 shares of the company’s stock worth $4,682,000 after buying an additional 133,342 shares during the last quarter. Institutional investors own 62.63% of the company’s stock.

Tectonic Therapeutic Company Profile

Tectonic Therapeutic, Inc engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.